PrE0502 – An Open-Label, Randomized, Phase IIIb Trial Evaluating the Efficacy and Safety of Standard of Care +/- Continuous Bevacizumab Treatment Beyond Progression of Disease in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) after First-Line Treatment with Bevacizumab Plus a Platinum Doublet-Containing Chemotherapy

Physician and Research Staff Educational Materials:

These materials are intended for promotional use among healthcare professionals and are NOT intended for use as patient educational materials.

  • Pocket Reference Card: trial schema, study objectives, and eligibility requirements on a pocket-sized card for easy reference when consulting with patients in the office or on rounds.

Additional Information on Displayed below is an interactive view of the study record as it appears in the government registry. If you are experiencing technical difficulties with this view, visit and search for record NCT01351415.